Price of one tube of amivantamab in 2025

Amivantamab (amivantamab), as a new type of targeted therapy, has been launched in China, but it has not yet been included in medical insurance and the price is relatively high. The specification of evantumumab is 350mg, and the domestic price is about more than 7,000 yuan per box. The specific price may fluctuate slightly according to different sales channels and regions. For Hong Kong version of original drugs, the price is usually around RMB 8,000. This is also due to the price setting in the Hong Kong market and the impact of import costs.

In foreign markets, the price of evantumumab is significantly higher. For example, in the European market, the price of evantumumab is approximately RMB 20,000 per box. This price is subject to exchange rate fluctuations and is therefore subject to change. In addition, since there is currently no generic version of evantumumab on the market, its price has not faced significant competitive pressure and remains at a high level.

Since evantumumab is a targeted drug targeting specific mutations (such asEGFR and MET mutations), its high selling price is mainly related to its research and development costs, market positioning and exclusivity of new drugs. For patients with non-small cell lung cancer, although the efficacy of the drug may significantly improve the treatment effect, the price may become an economic burden that cannot be ignored. Especially in the absence of medical insurance coverage, patients may have to bear the cost of treatment themselves, which may pose a certain financial pressure to some patients, especially ordinary people.

In the future, as more generic drugs are developed and launched, the market price of evantumumab may decline. However, its current high price limits its use in treatment. In addition, some areas may offer medication assistance programs or other financial support to help patients reduce the burden of treatment costs.

Reference materials:https://www.rybrevant.com/